Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

This study has been completed.
Sponsor:
Collaborator:
Yale University
Information provided by (Responsible Party):
Kimberly Yonkers, Yale University
ClinicalTrials.gov Identifier:
NCT00965562
First received: August 24, 2009
Last updated: August 7, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to compare the efficacy of calcium carbonate to fluoxetine in the treatment of moderate to severe PMS. Second, to compare each active agent to a placebo control. Third, to evaluate the efficacy of each treatment for specific symptom clusters (i.e. affective and somatic). Fourth, to determine whether the addition of calcium to on going fluoxetine treatment leads to additional therapeutic benefit.


Condition Intervention
Premenstrual Syndrome
Drug: Fluoxetine
Drug: Calcium
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Parallel Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

Resource links provided by NLM:


Further study details as provided by Donaghue Medical Research Foundation:

Primary Outcome Measures:
  • First, to compare the efficacy of calcium carbonate to fluoxetine in the treatment of moderate to severe PMS. Second, to compare each active agent to a placebo control. [ Time Frame: 6-7 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Third, to evaluate the efficacy of each treatment for specific symptom clusters (i.e. affective and somatic). Fourth, to determine whether the addition of calcium to on going fluoxetine treatment leads to additional therapeutic benefit. [ Time Frame: 6-7 months ] [ Designated as safety issue: No ]

Enrollment: 49
Study Start Date: September 2000
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: I
Fluoxetine
Drug: Fluoxetine
Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
Other Name: Prozac
Active Comparator: II
Calcium
Drug: Calcium
1200 mg of calcium to be taken for 5 menstrual cycles.
Placebo Comparator: III Drug: Placebo
For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.

Detailed Description:

This is a double blind, randomized, placebo controlled, parallel study that will randomize 60 women at the Yale site into treatment. Participants will be screened at various collaborating ob-gyn centers for possible PMS symptoms, and direct referrals from the community will also be accepted. Subject participation length is about 7 months with 6 scheduled study visits.

Methodology: After successfully completing the screening and qualification phase, participants will be randomized to treatment at Visit 1 for 5 cycles of double-blind treatment. Participants will be evaluated monthly during the randomization phase for adverse events, concurrent medication, and primary and secondary efficacy variables.

.

  Eligibility

Ages Eligible for Study:   18 Years to 48 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female outpatients between the ages of 18 and 48 who are:

    • Menstruating
    • Meet criteria for moderate to severe PMS
    • Report PMS symptoms for at least 9 our of the 12 months prior to screening; 4) *Are using an adequate method of birth control.

Exclusion Criteria:

  • Any candidate who:

    • Fulfills MINI (DSM-IV) criteria for a serious AXIS 1 disorder
    • Fulfills DSM-IV criteria during the charting phase consistent with a diagnosis of psychotic disorder, bipolar disorder or major depressive disorder
    • Has a severe, co-existing condition that, in the investigator's opinion, renders the patient unsuitable for the study
    • Poses a significant risk of suicide
    • Takes ongoing medication that could treat PMS symptoms
    • Has a history of hypersensitivity or adverse reaction to fluoxetine or calcium
    • Is lactating, pregnant or is planning to become pregnant during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00965562

Locations
United States, Connecticut
Yale School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Donaghue Medical Research Foundation
Yale University
Investigators
Principal Investigator: Kimberly A Yonkers, MD Yale School of Medicine
  More Information

No publications provided

Responsible Party: Kimberly Yonkers, Professor, Yale University
ClinicalTrials.gov Identifier: NCT00965562     History of Changes
Obsolete Identifiers: NCT00683605
Other Study ID Numbers: 0001011511
Study First Received: August 24, 2009
Last Updated: August 7, 2012
Health Authority: United States: Federal Government

Keywords provided by Donaghue Medical Research Foundation:
Premenstrual syndrome
PMS
calcium

Additional relevant MeSH terms:
Premenstrual Syndrome
Syndrome
Disease
Menstruation Disturbances
Pathologic Processes
Calcium, Dietary
Fluoxetine
Antidepressive Agents
Antidepressive Agents, Second-Generation
Bone Density Conservation Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014